Navegar por autor "Giraldo, P."

Mostrando ítems 1-5 de 5

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

2022- Luna, A.; Pérez-Lamas, L.; Boque, C.; Giraldo, P.; Xicoy, B.; [et al.]
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

2019- Penalver, F. J.; Marquez, J. A.; Duran, S.; Giraldo, P.; Martin, A.; [et al.]
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

2021- Garcia-Gutiérrez, V.; Luna, A.; Alonso-Dominguez, J.M.; Estrada, N.; Boque, C.; [et al.]
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

2015- Casado, L. F.; Garcia-Gutierrez, J. V.; Massague, I.; Giraldo, P.; Pérez Encinas, Manuel Mateo; [et al.]
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

2023- Pérez-Lamas, L.; Luna, A.; Boque, C.; Xicoy, B.; Giraldo, P.; [et al.]